Click image to view it in full size

According to industry estimates, the emergence of COVID-19 pandemic has changed the face of vaccines industry, as there is shift of focus on tech transfer in the industry with remarkable rise in the investment for COVID-19 vaccines development by government organizations. Funding by organizational collaborations during the pandemic have been driving the scale-up of vaccine production and engagement of stakeholders at various level with an aim of sharing the best practise of developing efficient vaccines.

In traditional vaccine industry, there is a shift from use of live attenuated or inactivated technologies to non-viral technologies, aiming to achieve increased scalability and turnaround time in vaccine development. The rising focus on prophylactic management of COVID-19 in 2021-2022 is anticipated to shift toward novel delivery modes of traditional vaccines and on highly prevalent disease areas, such as RSV, HIV, and cancer.